Sommario

• • ·Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study

    Pagina :563-566

    David J. Moliterno, PARAGON B International Steering Committee ∗

    Riassunto Riassunto
• • ·Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction

    Pagina :567-576

    Frank A. Sloan, Peter J. Rankin, David J. Whellan, Christopher J. Conover

    Riassunto Riassunto
• • ·Statins: Effective antiatherosclerotic therapy

    Pagina :577-583

    Roger S. Blumenthal

    Riassunto Riassunto
• • ·β-Blocker improvement in diastolic performance: The yin and yang of ventricular function changes

    Pagina :584-586

    Eric J. Eichhorn, Paul A. Grayburn

    
• • ·Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan

    Pagina :587-595

    Gordon W. Moe, Jean L. Rouleau, Lynne Charbonneau, Guy Proulx, J.Malcolm O. Arnold, Christian Hall, Jacques de Champlain, Aiala Barr, Pierre Sirois, Milton Packer

    Riassunto Riassunto
• • ·β-Blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by carvedilol

    Pagina :596-608

    Soccorso Capomolla, Oreste Febo, Marco Gnemmi, Giorgio Riccardi, Cristina Opasich, Angelo Caporotondi, Andrea Mortara, GianDomenico Pinna, Franco Cobelli

    Riassunto Riassunto
• • ·Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors

    Pagina :609-617

    Christopher B. Granger, Georg Ertl, Jerzy Kuch, Aldo P. Maggioni, John McMurray, Jean-Lucien Rouleau, Lynn Warner Stevenson, Karl Swedberg, James Young, Salim Yusuf, Robert M. Califf, Bradley A. Bart, Peter Held, Eric L. Michelson, Mary Ann Sellers, Gunilla Ohlin, Rodney Sparapani, Marc A. Pfeffer

    Riassunto Riassunto
• • ·Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension

    Pagina :618-623

    Antonio Augusto Lopes, Nair Yukie Maeda, Rilvani Cavalcante Gonçalves, Sérgio Paulo Bydlowski

    Riassunto Riassunto
• • ·Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: The EPICAL study

    Pagina :624-631

    M. Echemann, F. Zannad, S. Briançon, Y. Juillière, P.M. Mertès, J.M. Virion, J.P. Villemot

    Riassunto Riassunto
• • ·Reproducibility of neointima quantification with motorized intravascular ultrasound pullback in stented coronary arteries

    Pagina :632-637

    Evelyn Regar, Frank Werner, Johannes Rieber, Karl Theisen, Harald Mudra, Voker Klauss, Uwe Siebert

    
• • ·Multivessel coronary stenting versus bypass surgery in patients with multivessel coronary artery disease and normal left ventricular function: Immediate and 2-year long-term follow-up

    Pagina :638-642

    Sang-Wook Kim, Myeong-Ki Hong, Cheol Whan Lee, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park

    
• • ·Role of intracoronary ultrasound after high-pressure stent implantation

    Pagina :643-648

    James W. Choi, Gil M. Vardi, Sheridan N. Meyers, Michelle A. Parker, Lynne M. Goodreau, Charles J. Davidson

    
• • ·Sex differences in coronary artery size assessed by intravascular ultrasound

    Pagina :649-652

    Stuart E. Sheifer, Michael R. Canos, Kevin P. Weinfurt, Umesh K. Arora, Farrell O. Mendelsohn, Bernard J. Gersh, Neil J. Weissman

    Riassunto Riassunto
• • ·Three-dimensional helical computed tomographic angiography in neonates and infants with complex congenital heart disease

    Pagina :653-660

    Teruhiro Kawano, Masahiro Ishii, Junichi Takagi, Yasuki Maeno, Genju Eto, Yoko Sugahara, Takeshi Toshima, Hiroshi Yasunaga, Takemi Kawara, Kageshige Todo, Hirohisa Kato

    Riassunto Riassunto
• • ·Peripheral resistance vessel dysfunction in Marfan syndrome

    Pagina :661-666

    Motoyuki Nakamura, Shigehiro Itoh, Shinji Makita, Atsushi Ohira, Naoshi Arakawa, Katsuhiko Hiramori

    Riassunto Riassunto
• • ·Vasodilation with felodipine in chronic asymptomatic aortic regurgitation

    Pagina :667-674

    Lars Søndergaard, Jan Aldershvile, Per Hilderbrandt, Henning Kelbæk, Freddy Ståhlberg, Carsten Thomsen

    Riassunto Riassunto
• • ·Detection of angiographically significant coronary artery disease with accelerated intermittent imaging after intravenous administration of ultrasound contrast material

    Pagina :675-683

    Jucyléa Cwajg, Feng Xie, Edward O'Leary, David Kricsfeld, Howard Dittrich, Thomas R. Porter

    Riassunto Riassunto
• • ·Signal-averaged P-wave abnormalities and atrial size in patients with and without idiopathic paroxysmal atrial fibrillation

    Pagina :684-689

    Naoko Ishimoto, Makoto Ito, Masahiko Kinoshita

    Riassunto Riassunto
• • ·Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias

    Pagina :690-695

    Richard I. Fogel, John M. Herre, Harry A. Kopelman, Peter R. Kowey, Richard G. Trohman, Naomi Fineberg, Eric N. Prystowsky

    Riassunto Riassunto
• • ·Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

    Pagina :696-703

    Mary A. Mascelli, Neal S. Kleiman, Stanley J. Marciniak, Lakshmi Damaraju, Harlan F. Weisman, Robert E. Jordan

    Riassunto Riassunto
• • ·Benefits of magnesium in acute myocardial infarction: Timing is crucial

    Pagina :703

    Geeta Gyamlani, Chirag Parikh, Arvind G. Kulkarni

    
• • ·Alcohol consumption and plasminogen activator inhibitor type 1: The national heart, lung, and blood Institute family heart study

    Pagina :704-709

    Luc Djoussé, James S. Pankow, Donna K. Arnett, Yuqing Zhang, Yuling Hong, Michael A. Province, R. Curtis Ellison

    Riassunto Riassunto
• • ·Right ventricular function in patients with first inferior myocardial infarction: Assessment by tricuspid annular motion and tricuspid annular velocity

    Pagina :710-715

    Mahbubul Alam, Johan Wardell, Eva Andersson, Bassem A. Samad, Rolf Nordlander

    Riassunto Riassunto
• • ·Impact of Doppler-derived left ventricular diastolic performance on exercise capacity in normal individuals

    Pagina :716-722

    Hiroyuki Okura, Hiroo Inoue, Miyo Tomon, Shoji Nishiyama, Tadashi Yoshikawa, Kiyoshi Yoshida, Junichi Yoshikawa

    Riassunto Riassunto
• • ·Aortic root dilatation among young competitive athletes: Echocardiographic screening of 1929 athletes between 15 and 34 years of age

    Pagina :723-728

    Norimitsu Kinoshita, Jun Mimura, Chiyomi Obayashi, Fuminori Katsukawa, Shohei Onishi, Hajime Yamazaki

    Riassunto Riassunto
• • ·Changes in lipoprotein(a) concentration after orthotopic heart transplantation

    Pagina :729-733

    David DeNofrio, Shashank Desai, Daniel J. Rader, Gene Chang, Michael P. Kelley, Michael A. Acker, Evan Loh

    Riassunto Riassunto
• • ·Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events?

    Pagina :734-738

    Jerome D. Cohen, John H. Drury, Jamie Ostdiek, Jane Finn, B.R. Veerendra Babu, Gregory Flaker, Kathy Belew, Thomas Donohue, Arthur Labovitz

    Riassunto Riassunto
• • ·Long-term estrogen replacement therapy is associated with improved exercise capacity in postmenopausal women without known coronary artery disease

    Pagina :739-744

    Rita F. Redberg, Masami Nishino, Doff B. McElhinney, Michael W. Dae, Elias H. Botvinick

    Riassunto Riassunto
• • ·Introduction

    Pagina :S131

    Robert Califf, Monica Shah

    
• • ·Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials

    Pagina :S133

    Robert Temple

    
• • ·Challenges in the conduct and interpretation of phase II (pilot) randomized trials

    Pagina :S136

    Salim Yusuf

    
• • ·The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials

    Pagina :S143

    Christopher M. O'Connor, Wendy A. Gattis, Thomas J. Ryan

    
• • ·Economic end points in phase II trials

    Pagina :S155

    Daniel B. Mark, Tracey A. Simons

    
• • ·Select-drop designs in clinical trials

    Pagina :S158

    Susan S. Ellenberg

    
• • ·Sample size and interim analysis issues for dose selection

    Pagina :S161

    Kerry L. Lee

    
• • ·Equivalence and noninferiority trials

    Pagina :S166

    Jay P. Siegel

    
• • ·Design and interpretation of equivalence trials

    Pagina :S171

    Thomas R. Fleming

    
• • ·Estimating the distribution of quality-adjusted life with censored data

    Pagina :S177

    Anastasios A. Tsiatis

    
• • ·Chronic ischemic heart disease

    Pagina :S182

    Michael Gent, Robert M. Califf

    
• • ·Acute ischemic heart disease

    Pagina :S189

    Christopher B. Granger, Allan Skene

    
• • ·Surrogate end points in cardiovascular disease trials

    Pagina :S193

    Thomas R. Fleming

    
• • ·An FDA perspective on antiarrhythmic drugs in phase II trials

    Pagina :S197

    Raymond Lipicky

    
• • ·The development of antiarrhythmic drugs

    Pagina :S200

    Lloyd Fisher

    
• • ·Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure

    Pagina :S202

    Milton Packer

    
• • ·Design of phase II trials in congestive heart failure

    Pagina :S207

    David L. DeMets